Answers are grounded in this paper and cite their sources.
The presence of significant histologic inflammatory activity—e.g., proliferative lupus nephritis, LN—in kidney biopsy from patients with systemic lupus erythematosus (SLE) and minimal or absent urinary abnormalities is increasingly recognized. Available studies report proliferative lesions in a variable but significant proportion of patients with proteinuria below the 0.5 g/day threshold currently recommended by major guidelines for biopsy indication, raising concerns about delayed diagnosis and treatment. In this narrative review, we summarize the available evidence on kidney biopsy findings in SLE patients with low-grade proteinuria, both at initial diagnostic biopsy and at repeat biopsy. We also report, when available, the association of serological markers (e.g., anti-dsDNA antibodies, complement levels) and histological activity in this population, acknowledging limitations and the absence of clear specific cut-offs. Additionally, we address the risk of biopsy-related complications to provide clinicians with a balanced framework for individualized decision-making in this scenario. The cumulative evidence suggests that current guideline proteinuria thresholds for kidney biopsy may be insufficiently sensitive for exclusion of significant histological activity, though prospective validation is needed.
No takes yet. Share an insight, caveat, or question.
Fontana et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: